Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET/CT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)

NCT07508852 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT07508852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07508852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET/CT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)
Lead sponsor
Peking University First Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 22, 2025
Completion date
December 31, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sclc, sclc, extensive stage, sclc, limited stage, small cell lung cancer, small cell lung cancer ( sclc )